Navigation Links
Effectiveness of progesterone in reducing preterm births may be altered by genetic predisposition
Date:1/29/2009

SAN DIEGO, CA, JAN. 30, 2009 New research that may explain why taking progesterone to prevent preterm birth is only effective for some women was unveiled today at the 29th Annual Society for Maternal-Fetal Medicine (SMFM) meeting The Pregnancy Meeting.

The drug, 17 alpha-hydroxyprogesterone caproate (or 17P), a synthetic form of the progesterone hormone naturally produced during pregnancy, has been demonstrated in clinical trials to prevent some recurrent preterm births but not all.

"This study helps strengthen the theory that genetic variation in the human progesterone receptor plays an important role in the effectiveness of 17P," states Tracy Manuck, M.D., study author and SMFM member.

Women who have a spontaneous preterm delivery are at greatly increased risk of preterm delivery in subsequent pregnancies. Preterm birth is a leading cause of infant death in the United States and babies who survive face serious lifelong health problems. More than 543,000 babies are born too soon each year and recent federal statistics show that the nation's preterm birth rate has risen to 12.8 percent -- a 36 percent increase since the early 1980s.

"Dr. Manuck's research gives us a tantalizing clue as to why 17P works for some women, but not for others," said Alan R. Fleischman, M.D., senior vice president and medical director of the March of Dimes. "With further research along these lines, we hope to someday be able to prevent preterm birth from happening in the first place by screening women before they get pregnant, and identifying those whose babies could get a healthy start in life with the help of 17P."

The research, which was sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Unit Network and the University of Utah, assessed whether women with genetic variations known as single nucleotide polymorphisms (SNPs) in the human progesterone receptor gene we
'/>"/>

Contact: Elizabeth Lynch
elynch@marchofdimes.com
914-997-4286
March of Dimes Foundation
Source:Eurekalert

1

GOOD

Page: 1 2

Related biology news :

1. UC health news: molecular pathway may predict chemotherapy effectiveness
2. Socioeconomic position associated with effectiveness of HIV drugs
3. MIT model could improve some drugs effectiveness
4. Trial seeks genetic fingerprint for predicting drug effectiveness
5. Quantitative PET imaging finds early determination of effectiveness of cancer treatment
6. Poll Shows Strong Doubts About Effectiveness of Federal Employment Verification System
7. New studies on the Mediterranean diet confirm its effectiveness for chronic disease prevention
8. RNA molecules, delivery system improve vaccine responses, effectiveness
9. New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning
10. Research shows cells inactive state is critical for effectiveness of cancer treatment
11. Corazonas Foods and Brandeis University partner to create cholesterol-reducing snacks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... NEW YORK , May 16, 2013 ... market research report is available in its ... Market Forecast & Opportunities, 2018 ... data protection and old security practises such ... driven the growth of biometric technologies in ...
(Date:5/15/2013)... gout risk, new research reveals that vitamin C, also ... levels to a clinically significant degree in patients with ... with allopurinol, appears to have a weak effect on ... the results published in the American College of Rheumatology ... Gout is an inflammatory arthritis that causes excruciating pain ...
(Date:5/15/2013)... to date to examine the efficacy of PARP inhibitor ... breast and ovarian cancer, the oral drug olaparib was ... cancers. Results of the study, led by researchers from ... Pennsylvania and Sheba Medical Center in Tel Hashomer, Israel, ... Oncology,s annual meeting in Chicago in early June (Abstract ...
Breaking Biology News(10 mins):Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7Vitamin C does not lower uric acid levels in gout patients 2PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2
... MADISON, WI, September 29, 2008 A plot of ... 110 years of sustainable farming practices can produce similar ... In 1896, Professor J.F. Duggar at the Agricultural ... an experiment to test his theories that sustainable cotton ...
... video clip of Leonard Kleinrock showing his contributions to ... George W. Bush will award the National Medals of ... leading researchers, inventors and innovators, at a ceremony in ... a.m. on Monday, September 29, 2008. Reporters interested in ...
... that inexpensive device boosts fuel economy by up to 20 ... prices, researchers in Pennsylvania are reporting results of laboratory tests ... to a car engine,s fuel injector can boost gas mileage ... precious miles per gallon, they say. Their study is scheduled ...
Cached Biology News:Experiment demonstrates 110 years of sustainable agriculture 28 National Medals of Science awardees to be honored at gala, then the White House 28 National Medals of Science awardees to be honored at gala, then the White House 38 National Medals of Science awardees to be honored at gala, then the White House 48 National Medals of Science awardees to be honored at gala, then the White House 58 National Medals of Science awardees to be honored at gala, then the White House 68 National Medals of Science awardees to be honored at gala, then the White House 78 National Medals of Science awardees to be honored at gala, then the White House 8American Chemical Society's Weekly PressPac -- Sept. 24, 2008 2American Chemical Society's Weekly PressPac -- Sept. 24, 2008 3American Chemical Society's Weekly PressPac -- Sept. 24, 2008 4American Chemical Society's Weekly PressPac -- Sept. 24, 2008 5American Chemical Society's Weekly PressPac -- Sept. 24, 2008 6American Chemical Society's Weekly PressPac -- Sept. 24, 2008 7American Chemical Society's Weekly PressPac -- Sept. 24, 2008 8
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
(Date:5/17/2013)... May 17, 2013  Insero Health, Inc., a company ... epilepsy and related neurological disorders, is today reporting top-line ... compound INS001 in patients with drug-resistant epilepsy.  The data ... Trials (AED) Xll meeting by Dr. Steven ... of Insero,s Scientific Advisory Board.  In this study, INS001 ...
(Date:5/17/2013)... MD (PRWEB) May 17, 2013 ... of ezColony version 4.1, a versatile refinement to ... premier software solution, improves its advanced methodical management ... facilities with ezColony 4.1. The network-based platform provides ... conduct effective research. While continuing to emphasize streamlined ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Tooth decay is ... showing active signs of the disease. The World Health Organization ... nearly 100% of adults have cavities. What are the long-term ... is showing a strong connection between the oral bacterial imbalance ... this disease so rampant, yet it is also 100% preventable? ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... , , SOUTH PLAINFIELD, ... the initiation of a Phase 3 trial of ataluren (formerly ... mutation cystic fibrosis (nmCF). Patients with CF lack adequate ... a chloride channel necessary for normal function of the lung, ...
... , , INDIANAPOLIS, Sept. 10 ... Advanced lithium-ion battery maker EnerDel, Inc. today named Richard L. Stanley ... global manufacturing and management experience and a distinguished record of creating ... appointments designed to position EnerDel for continued success in the next ...
... , OXFORD, England, September ... Watkins as Head of the Product & Portfolio,Strategy ... Senior Advisors,and Analysts. , ... "We are,delighted to welcome Nikki to PharmaVentures. Our ...
Cached Biology Technology:PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 3PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 4PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 5PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 6Lithium-Ion Battery Maker Names New President 2Lithium-Ion Battery Maker Names New President 3Lithium-Ion Battery Maker Names New President 4Lithium-Ion Battery Maker Names New President 5Lithium-Ion Battery Maker Names New President 6PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy 2
... Spin Columns contain a proprietary high-performance desalting ... desalting and protein-recovery characteristics compared to other ... as 25 g/ml of protein can be ... 95% retention of salts and other small ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
... is a G1 cyclin required for G1-phase ... a proto-oncogene. cyclin D2 can phosphorylate ... Species Reactivity: Human, Mouse, and Rat. ... is particularly well suited for neutralization of ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
Biology Products: